Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | FASN | P49327 | 7/20 | 0.37 |
| ▸ | AR | P10275 | 5/20 | 0.37 |
| ▸ | PDE5A | O76074 | 1/20 | 0.36 |
| ▸ | PDE4A | P27815 | 1/20 | 0.36 |
| ▸ | PDE1A | P54750 | 1/20 | 0.36 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.36 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.36 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.36 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.36 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.36 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.36 |
| ▸ | LIPC | P11150 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | JAK1 | P23458 | 1/20 | 0.35 |
| ▸ | JAK3 | P52333 | 1/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.35 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17844691 | 0.86 | MKNK1 (0.48) | HPGDJAK2MKNK1MKNK2 | |
| SCHEMBL18529789 | 0.85 | PAK4 (0.43) | FASNLIPCSLC6A7 | |
| SCHEMBL19753619 | 0.82 | P2RY12 (0.40) | FASNPDE5APDE4APDE1APDE1B | |
| SCHEMBL17844696 | 0.82 | LIPC (0.40) | HPGDFASNPDE5APDE4APDE1A | |
| SCHEMBL17844709 | 0.80 | PDE5A (0.37) | HPGDFASNPDE5APDE4APDE1A | |
| SCHEMBL19742287 | 0.79 | PAK4 (0.40) | FASNLIPCJAK2JAK1JAK3 | |
| SCHEMBL31622708 | 0.74 | PDE5A (0.41) | HPGDFASNPDE5APDE4APDE1A | |
| SCHEMBL18529770 | 0.72 | LRRK2 (0.47) | HPGDFASNPDE5APDE4APDE1A | |
| SCHEMBL18530550 | 0.72 | FASN (0.44) | HPGDFASNPDE5APDE4APDE1A | |
| SCHEMBL18529798 | 0.71 | HSD11B1 (0.42) | HPGDFASNPDE5APDE4APDE1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10858347-B2 | Multicyclic compounds and uses thereof | Karyopharm Therapeutics Inc. (US) | 2020-12-08 | — | — | US | disclosed |
| US-10858347-B2 | Multicyclic compounds and uses thereof | Karyopharm Therapeutics Inc. (US) | 2020-12-08 | — | — | US | disclosed |
| US-20190016710-A1 | MULTICYCLIC COMPOUNDS AND USES THEREOF | Karyopharm Therapeutics Inc. | 2019-01-17 | — | — | US | disclosed |
| US-20190016710-A1 | MULTICYCLIC COMPOUNDS AND USES THEREOF | Karyopharm Therapeutics Inc. | 2019-01-17 | — | — | US | disclosed |
| US-20180244660-A1 | CYCLOPROPYLDERIVATIVES AND THEIR USE AS KINASE INHIBITORS | Karyopharm Therapeutics Inc. | 2018-08-30 | — | — | US | disclosed |
| US-20170369470-A1 | Cyclic Compounds and Uses Thereof | Karyopharm Therapeutics Inc. | 2017-12-28 | — | — | US | disclosed |
| WO-2017117447-A1 | MULTICYCLIC COMPOUNDS AND USES THEREOF | Karyopharm Therapeutics Inc. (US) | 2017-07-06 | — | — | WO | disclosed |
| WO-2017031204-A1 | CYCLOPROPYLDERIVATIVES AND THEIR USE AS KINASE INHIBITORS | Karyopharm Therapeutics Inc. (US) | 2017-02-23 | — | — | WO | disclosed |
| WO-2017031204-A1 | CYCLOPROPYLDERIVATIVES AND THEIR USE AS KINASE INHIBITORS | Karyopharm Therapeutics Inc. (US) | 2017-02-23 | — | — | WO | disclosed |
| WO-2016100515-A1 | CYCLIC COMPOUNDS AND USES THEREOF | Karyopharm Therapeutics Inc. (US) | 2016-06-23 | — | — | WO | disclosed |
| WO-2016100515-A1 | CYCLIC COMPOUNDS AND USES THEREOF | Karyopharm Therapeutics Inc. (US) | 2016-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180244660-A1 | CYCLOPROPYLDERIVATIVES AND THEIR USE AS KINASE INHIBITORS | MALT1, BCL9, IKBKE | HPGD 1232/4885FASN 2195/4885AR 1883/4885 |
| US-20170369470-A1 | Cyclic Compounds and Uses Thereof | MALT1, BCL9, BCL6 | HPGD 2479/4885FASN 3614/4885AR 1685/4885 |
| US-20190016710-A1 | MULTICYCLIC COMPOUNDS AND USES THEREOF | MALT1, BCL9, BCL6 | HPGD 2142/4885FASN 4071/4885AR 2993/4885 |
| US-10858347-B2 | Multicyclic compounds and uses thereof | MALT1, BCL9, BCL6 | HPGD 2142/4885FASN 4071/4885AR 2993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.